Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae

Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation

(2017) Fiorella Krapp et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

(2017) Matthew Sims et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae

(2017) Zhen Shen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

(2016) David C. Griffith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying bla KPC Collected in U.S. Hospitals from 2012 to 2015

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa

(2016) Kazuhiro Oshima et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape

(2016) R. M. Humphries et al.   CLINICAL INFECTIOUS DISEASES

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams

(2016) Dustin T. King et al.   PROTEIN SCIENCE

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects

(2015) Eric Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

(2015) Scott J. Hecker et al.   JOURNAL OF MEDICINAL CHEMISTRY

Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

(2014) George L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations

(2014) S Nambiar et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study

(2014) Frédéric Frippiat et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroActivity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients

(2013) B. Balandin Moreno et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

(2012) Pratik Bhagunde et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

(2012) M. Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia

(2011) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy

(2011) J. Findlay et al.   CLINICAL MICROBIOLOGY AND INFECTION

Pharmacokinetic‐Pharmacodynamic Considerations in the Design of Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia Studies: Look before You Leap!

(2010) Paul G. Ambrose et al.   CLINICAL INFECTIOUS DISEASES

Challenges in Anti‐Infective Development in the Era of Bad Bugs, No Drugs: A Regulatory Perspective Using the Example of Bloodstream Infection as an Indication

(2010) Helen W. Boucher   CLINICAL INFECTIOUS DISEASES

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection

(2010) Elizabeth B. Hirsch et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Emergence of carbapenem-non-susceptible extended-spectrum  -lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tubingen, Germany

(2009) S. Grobner et al.   JOURNAL OF MEDICAL MICROBIOLOGY